Imunon (NASDAQ: IMNN) grants 12,667 stock options to its CMO

Rhea-AI Filing Summary

Imunon, Inc. Chief Medical Officer Douglas Vincent Faller reported a new stock option grant for 12,667 shares of common stock. The options were granted on January 2, 2026 with an exercise price of $3.95 per share, equal to the closing price of Imunon common stock on the grant date. The filing shows the options were acquired at a price of $0 as part of an equity award and are held directly.

The options vest over time: one-half of the grant vests on the grant date, one-quarter on the first anniversary, and the remaining one-quarter on the second anniversary of the grant date. The options are exercisable through January 2, 2036, providing the CMO with long-term equity-based incentives tied to Imunon’s share price performance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Faller Douglas Vincent

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NJ 08648

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.95(1)	01/02/2026		A		12,667		01/02/2026(2)	01/02/2036	Common Stock	12,667	$0	12,667	D

Explanation of Responses:

1. Represents the closing price of Imunon, Inc. Common Stock on the date of the grant

2. The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant.

	/s/ Susan Eylward, Attorney-in-Fact for Douglas V. Faller	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Imunon (IMNN) report in this Form 4?

The report shows that Chief Medical Officer Douglas Vincent Faller received a grant of 12,667 stock options to buy Imunon common stock.

What is the exercise price of the Imunon (IMNN) stock options granted to the CMO?

The stock options have an exercise price of $3.95 per share, which represents the closing price of Imunon common stock on the January 2, 2026 grant date.

How do the Imunon (IMNN) stock options granted to the CMO vest?

The options vest in stages: 1/2 vests on the grant date, 1/4 vests on the one-year anniversary, and 1/4 vests on the two-year anniversary of the January 2, 2026 grant date.

When do the Imunon (IMNN) CMO stock options expire?

The stock options granted to the Chief Medical Officer expire on January 2, 2036, giving a ten-year term from the grant date.

How many derivative securities does the Imunon (IMNN) CMO hold after this transaction?

Following this grant, the Chief Medical Officer beneficially owns 12,667 stock options, held in direct ownership.

Did the Imunon (IMNN) CMO pay anything for these stock options on grant?

No cash was paid at grant; the options were acquired at a price of $0 as an equity award, with a strike price of $3.95 per share for future exercises.